Kazia Therapeutics

This cancer drug developer has Paxalisib as its lead candidate. Paxalisib works by hitting a cellular signalling pathway called PI3K / Akt / mTOR that is a central regulator of growth and cell division. It can go badly wrong when cancer gets started. The drug is being evaluated in eight clinical studies but, significantly, it entered Phase 3 in glioblastoma, the most common of the primary brain cancers, with the commencement of the GBM AGILE study in January 2021. We think Kazia’s maturity can prompt a re-rating, especially as the Phase 2 data for Paxalisib was favourable. Paxalisib has Orphan Drug Designation from the FDA and, importantly, Rare Pediatric Disease Designation for a condition called Diffuse Intrinsic Pontine Glioma, that brings with it the potential for a valuable Priority Review Voucher.

Read the most recent article on KZA here